CompletedNCT01193153
Paliperidone Injections to Prevent Schizoaffective Relapse
About this title
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
Read the official source — NCT01193153Medication studyAges 18–65Multiple countriesSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Garden Grove and 79 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateSeptember 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 667
- Sponsor
- Janssen Scientific Affairs, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Bulgaria, India, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01193153
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
Get this study by email
Recruitment & locations
CompletedGarden Grove, United States · Oakland, United States · Oceanside, United States
77 more locations
- Pico Rivera, United States
- Riverside, United States
- San Diego, United States
- Torrance, United States
- Denver, United States
- Hollywood, United States
- Maitland, United States
- North Miami, United States
- Tampa, United States
- Atlanta, United States
- Marietta, United States
- Schamburg, United States
- Wichita, United States
- Flowood, United States
- Creve Coeur, United States
- Cedarhurst, United States
- Staten Island, United States
- Charlotte, United States
- Cleveland, United States
- Philadelphia, United States
- Arlington, United States
- Austin, United States
- Dallas, United States
- Irving, United States
- San Antonio, United States
- Pleven, Bulgaria
- Plovdiv, Bulgaria
- Rousse, Bulgaria
- Sofia, Bulgaria
- Ahmedabad, India
- Aurangabad, India
- Chennai, India
- Jaipur, India
- Lucknow Gpo, India
- Mangalore, India
- Mysore, India
- Nashik, India
- Pune, India
- Uttar Pradesh, India
- Vadadora, India
- Varanasi, India
- Vijaywada, India
- Alor Star, Malaysia
- Ipoh, Malaysia
- Kota Bharu, Malaysia
- Kota Kinabalu, Malaysia
- Kuala Lumpur, Malaysia
- Tanjong Rambutan, Malaysia
- Cebu, Philippines
- Davao City, Philippines
- Iloilo City, Philippines
- Quezon City, Philippines
- Arad, Romania
- Bucharest, Romania
- Cluj-Napoca, Romania
- Craiova, Romania
- Oradea, Romania
- Sibiu, Romania
- Timișoara, Romania
- Cape Town, South Africa
- Centurion Gauteng, South Africa
- Durban, South Africa
- George, South Africa
- Johannesburg, South Africa
- Pretoria, South Africa
- Tyger Valley, South Africa
- Dnipropetrovsk, Ukraine
- Donetsk, Ukraine
- Hlevakha, Ukraine
- Ivano-Frankivsk, Ukraine
- Kharkiv, Ukraine
- Kiev, Ukraine
- Poltava, Ukraine
- Simferopol, Ukraine
- Uzhhorod, Ukraine
- Village Stepanovka Kherson, Ukraine
- Vinnitsa, Ukraine
Questions about this study
Who is behind this study?
The study sponsor is Janssen Scientific Affairs, LLC.
Did this study involve medication?
Yes. The study involved medication, including Placebo and paliperidone palmitate.
Who was this study for?
Listed age limits: 18 years to 65 years.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia